As of 2025-07-04, the Intrinsic Value of SpringWorks Therapeutics Inc (SWTX) is (161.98) USD. This SWTX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 46.99 USD, the upside of SpringWorks Therapeutics Inc is -444.7%.

The range of the Intrinsic Value is (866.73) - (92.54) USD.

Is SWTX undervalued or overvalued?

Based on its market price of 46.99 USD and our intrinsic valuation, SpringWorks Therapeutics Inc (SWTX) is overvalued by 444.7%.

Note: result may not be accurate due to the invalid valuation result of DCF model.

46.99 USD

Stock Price

(161.98) USD

Intrinsic Value

Intrinsic Value Details

SWTX Intrinsic Value - Valuation Summary

	Range	Selected	Upside
a
DCF (Growth Exit 5Y)	(866.73) - (92.54)	(161.98)	-444.7%
Peter Lynch Fair Value	-16.86 - -16.86	-16.86	-135.87%
P/E Multiples	(59.00) - (81.66)	(72.91)	-255.2%
EV/EBITDA Multiples	(64.48) - (46.88)	(66.27)	-241.0%

SWTX Intrinsic Value - Peers Comparison

	Range	Selected	Upside
a
Abbvie Inc	59.01 - 369.54	115.21	-39.1%
Amgen Inc	184.69 - 828.17	326.99	9.6%
Gilead Sciences Inc	17.78 - 97.79	34.67	-69.0%
Regeneron Pharmaceuticals Inc	437.98 - 999.89	599.19	9.5%
Amicus Therapeutics Inc	(0.13) - 1.39	0.17	-97.2%

SWTX Intrinsic Value - Key Valuation Metrics

Market Cap (mil)	3,539
Beta	1.03
Outstanding shares (mil)	75
Enterprise Value (mil)	3,476

Market risk premium	5.1%
Cost of Equity	8.25%
Cost of Debt	5%
WACC	6.0%